Search This Blog

Thursday, June 5, 2025

Ocugen to License Modifier Gene Therapy for Retinitis Pigmentosa in Korea

 

  • Upfront fees and near-term development milestone payments totaling up to $11 million
  • Sales milestones of $150 million or more in first 10 years of commercialization
  • Royalties equaling 25% of net sales
  • Ocugen to manufacture and supply OCU400

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.